Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CN401 in relapsed or refractory peripheral T-cell lymphoma and NK/T-cell lymphoma
ChiCTR2100048948Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tenalisib in peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTL) (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Safety, Tolerability and 3 more. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
tenalisib
03
Conditions
peripheral T-cell lymphoma (PTCL)natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on ChiCTR2100048948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048948.